Tobias Schmidt
Senior Vice President & Head of Discovery DISCO Pharmaceuticals
Tobias serves as Senior Vice President Discovery overseeing platform, target validation and preclinical development at DISCO Pharmaceuticals. Tobias is a target validation expert with several years of drug development experience in the pharmaceutical industry.
Before joining DISCO, Tobias was a Team and Project Lead at Hoffman-La Roche, where he established and led a target discovery & validation group with a focus on genetic screens to identify targets in the field of cancer immunotherapy.
Tobias holds a PhD in Molecular Biomedicine from the University of Bonn, Germany, where he worked on pattern recognition receptors of the innate immune system and gene editing technologies as a tool for target identification.
Seminars
- Identifying proximal proteins on the cancer cell surface through DISCOtech, DISCOs proprietary surfaceome proteomics platform
- Leveraging DISCOtech for target pair discovery and multispecific drug development, allowing the combination of novel, proximal cancer target pairs that are mutually exclusive expressed on normal tissue
- Designing logic-gated mulitspecific ADCs and T-cell engagers, enabling the creation of ultra-clean, cancer-specific therapies
